BVF Inc’s MoonLake Immunotherapeutics MLTX Stock Holding History

BVF Inc’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312M	Hold	16,001,284	–	–	7.97%	4
2026 Q1	$298M	Sell	16,001,284 -3,750,000	-19%	-$62.1M	9.5%	2
2025 Q4	$260M	Hold	19,751,284	–	–	8.76%	3
2025 Q3	$142M	Hold	19,751,284	–	–	5.74%	4
2025 Q2	$932M	Hold	19,751,284	–	–	33.31%	1
2025 Q1	$772M	Hold	19,751,284	–	–	31.45%	1
2024 Q4	$1.07B	Sell	19,751,284 -2,000,000	-9%	-$102M	36.25%	1
2024 Q3	$1.1B	Hold	21,751,284	–	–	32.08%	1
2024 Q2	$956M	Hold	21,751,284	–	–	26.81%	1
2024 Q1	$1.09B	Hold	21,751,284	–	–	30.04%	1
2023 Q4	$1.31B	Hold	21,751,284	–	–	32.87%	1
2023 Q3	$1.24B	Hold	21,751,284	–	–	33.43%	1
2023 Q2	$1.11B	Hold	21,751,284	–	–	30.92%	1
2023 Q1	$465M	Hold	21,751,284	–	–	17.01%	1
2022 Q4	$228M	Hold	21,751,284	–	–	9.64%	1
2022 Q3	$173M	Hold	21,751,284	–	–	7.15%	1
2022 Q2	$114M	Buy	+21,751,284	New	+$137M	5.52%	2

Other funds holding MLTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BVF Inc's MLTX Position: Q2 2026 in Review

BVF Inc held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 16,001,284 shares worth $312M. The position accounts for 7.97% of the portfolio, ranked #4.

BVF Inc first reported a position in MLTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.31B in Q4 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

BVF Inc held 16,001,284 shares of MoonLake Immunotherapeutics worth $312M as of Q2 2026.
BVF Inc left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
MoonLake Immunotherapeutics made up 7.97% of BVF Inc's portfolio in Q2 2026, its #4 holding.
BVF Inc first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 17 quarters since.
BVF Inc's MoonLake Immunotherapeutics position peaked at $1.31B in Q4 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.